GlassScriptPhysician profile
Manuel Fernandez
NPI 1285684753
$3,693.51
in general payments reported to CMS, 2019-2025
19 companies · $523 in 2025
The $523 reported for 2025 was more than what 93% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $347 · 2021: $941 · 2022: $318 · 2023: $579 · 2024: $489 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,591.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,294.16 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $589.83 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $547.26 | 2019-2022 | |
| Lilly USA, LLC | $500.77 | 2020-2024 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $197.65 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $117.47 | 2022 | |
| Janssen Pharmaceuticals, INC | $111.33 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $82.28 | 2020 | |
| Abbott Laboratories | $60.45 | 2021-2023 | Freestyle Libre |
| Astellas Pharma US INC | $42.56 | 2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $28.49 | 2025 | Zoryve |
| Daiichi Sankyo INC. | $20.22 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.63 | 2023 | Jardiance |
| Verity Pharmaceuticals INC. | $18.78 | 2025 | Tlando |
| Sanofi-Aventis U.S. LLC | $17.92 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $17.00 | 2022 | |
| Glaxosmithkline, LLC. | $13.94 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.77 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Fernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.